Incidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate cancer, two-thirds of which are novel targeted therapies or immunotherapies.
Posted over 2 years ago
Nanocrystals make dentures shine
Research team develops advanced live-imaging approach (w/ video)
Tunable nano-suspensions for light harvesting
Tagging tumors with gold: Scientists use gold nanorods to flag brain tumors
Laser Hardware/Control Software Engineer I (209) - Hanscom AFB, MA
Postdoctoral Position - La Jolla, CA
Research Engineer position in Super-resolution microscopy - Castelldefels (Barcelona), Spain
Physicist/Physical Chemist/Research Engineer (We Sponsor Clearances) - Lexington, MA
AACR 103rd Annual Meeting 2012
Conference on Lasers and Electro-Optics and the...
